Regular Article
Crohn's disease: step up or top down therapy

https://doi.org/10.1053/bega.2003.0361Get rights and content

Abstract

The concept of a ‘step-up’ or ‘top-down’ approach to the treatment of Crohn's disease has evolved from the impact of novel anti-TNF (anti-tumour necrosis factor) therapies that have been effective for patients who are refractory to other medical treatments. In addition, the potential to produce mucosal healing with anti-TNF treatments without the well-recognized systemic complications of glucocorticoid therapy has created debate as to whether earlier, more aggressive, therapies should be advocated. This controversy arises at a time when the concept of sequential therapy to induce and maintain remissions for Crohn's disease has begun to be accepted and precedes our ability to define the concept of disease modification or predict the natural history of Crohn's disease based upon clinical, pathological, molecular orgenetic criteria. Evidence for therapeutic efficacy in Crohn's disease is presented as a prologue to considerations necessary to determine the benefits and risks of early aggressive treatment versus sequential approaches based upon disease severity.

References (51)

  • C Prantera et al.

    Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial

    Gastroenterology

    (1999)
  • B Ursing et al.

    A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result

    Gastroenterology

    (1982)
  • JF Colombel et al.

    A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease

    American Journal of Gastroenterology

    (1999)
  • LJ Brandt et al.

    Metronidazole therapy for perineal Crohn's disease: a follow-up study

    Gastroenterology

    (1982)
  • WA Faubion et al.

    The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

    Gastroenterology

    (2001)
  • R Modigliani et al.

    Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance

    Gastroenterology

    (1996)
  • H Lochs et al.

    Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

    Gastroenterology

    (2000)
  • C Camma et al.

    Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

    Gastroenterology

    (1997)
  • P Rutgeerts et al.

    Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection (see comments)

    Gastroenterology

    (1995)
  • C Fiocchi

    Inflammatory bowel disease: etiology and pathogenesis

    Gastroenterology

    (1998)
  • L Genestier et al.

    Mechanisms of action of methotrexate

    Immunopharmacology

    (2000)
  • FJ Baert et al.

    Tumor necrosis factor alpha antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis (in process citation)

    Gastroenterology

    (1999)
  • C Fiocchi

    From immune activation to gut tissue injury: the pieces of the puzzle are coming together

    Gastroenterology

    (1999)
  • J Hampe et al.

    Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study

    Lancet

    (2002)
  • MD Silverstein et al.

    Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

    Gastroenterology

    (1999)
  • Cited by (0)

    View full text